RPH 104Alternative Names: RPH-104
Latest Information Update: 23 Feb 2016
At a glance
- Originator TRPHARM
- Class Anti-inflammatories
- Mechanism of Action Interleukin 1 beta inhibitors; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 01 Jan 2016 Phase-I clinical trials in Inflammation (In volunteers) in Turkey (SC)